Status:
COMPLETED
Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
Biogen
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the coorelation between patient factors, health care provider factors, drug factors and compliance in patients with relapsing forms of multiple sclerosis (RMS)...
Detailed Description
While compliance rates with interferons and glatiramer acetate treatment have been high when assessed in the context of controlled clinical trials, we have observed substantially less consistent rates...
Eligibility Criteria
Inclusion
- Diagnosis of relapsing form of multiple sclerosis
- Age 18 or older
- Therapy with disease modifying agent (Glatiramer acetate, Interferon Beta-1b, ot Interferon Beta 1a (IM or SC) for at least 6 months
- Access to the internet to complete the study survey
Exclusion
- Diagnosis of progressive forms of multiple sclerosis
- Therapy on DMA for less than 6 months
- Inability to complete the survey
- Participation in other investigational studies within the last 6 months
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
End Date :
September 1 2005
Estimated Enrollment :
1040 Patients enrolled
Trial Details
Trial ID
NCT00223457
Start Date
April 1 2004
End Date
September 1 2005
Last Update
January 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390